Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4521972
Max Phase: Preclinical
Molecular Formula: C38H40N6O11
Molecular Weight: 756.77
Molecule Type: Unknown
Associated Items:
ID: ALA4521972
Max Phase: Preclinical
Molecular Formula: C38H40N6O11
Molecular Weight: 756.77
Molecule Type: Unknown
Associated Items:
Canonical SMILES: NC[C@H]1O[C@@H](O[C@@H](Cc2cn(Cc3ccc(COc4ccc(C(=O)c5ccccc5)cc4)cc3)nn2)[C@H]2O[C@@H](n3ccc(=O)[nH]c3=O)[C@H](O)[C@@H]2O)[C@H](O)[C@@H]1O
Standard InChI: InChI=1S/C38H40N6O11/c39-17-28-31(47)34(50)37(54-28)53-27(35-32(48)33(49)36(55-35)44-15-14-29(45)40-38(44)51)16-25-19-43(42-41-25)18-21-6-8-22(9-7-21)20-52-26-12-10-24(11-13-26)30(46)23-4-2-1-3-5-23/h1-15,19,27-28,31-37,47-50H,16-18,20,39H2,(H,40,45,51)/t27-,28+,31+,32-,33+,34+,35+,36+,37+/m0/s1
Standard InChI Key: BFQARAORPOXDHX-BQKAZMJOSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 756.77 | Molecular Weight (Monoisotopic): 756.2755 | AlogP: -0.36 | #Rotatable Bonds: 14 |
Polar Surface Area: 246.50 | Molecular Species: BASE | HBA: 16 | HBD: 6 |
#RO5 Violations: 3 | HBA (Lipinski): 17 | HBD (Lipinski): 7 | #RO5 Violations (Lipinski): 3 |
CX Acidic pKa: 9.70 | CX Basic pKa: 8.75 | CX LogP: 0.95 | CX LogD: -0.17 |
Aromatic Rings: 5 | Heavy Atoms: 55 | QED Weighted: 0.08 | Np Likeness Score: 0.11 |
1. Patel B, Ryan P, Makwana V, Zunk M, Rudrawar S, Grant G.. (2019) Caprazamycins: Promising lead structures acting on a novel antibacterial target MraY., 171 [PMID:30933853] [10.1016/j.ejmech.2019.01.071] |
2. Serpi M, Ferrari V, Pertusati F.. (2016) Nucleoside Derived Antibiotics to Fight Microbial Drug Resistance: New Utilities for an Established Class of Drugs?, 59 (23): [PMID:27607900] [10.1021/acs.jmedchem.6b00325] |
Source(1):